UEECOTCOrthopedic, Prosthetic & Surgical Appliances & SuppliesUS GAAP · USD

United Health Products, Inc.

United Health Products, Inc. develops and markets patented hemostatic gauze products for wound care and surgical bleeding control. The company is based in the United States and operates through its CelluSTAT product line and related branded formats, with manufacturing and packaging performed through contract and service providers.

Liikevaihto0,0milj. USD
Liikevoitto (EBIT)−2,3milj. USD
−12,3 %v/v
Nettotulos−2,7milj. USD
−33,4 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2018–2025

−8−6−4−202milj. USD2018: 0,03 milj. USD2018: EBIT −1,9 milj. USD20182019: 0,00 milj. USD2019: EBIT −6,1 milj. USD20192022: 0,04 milj. USD2022: EBIT −2,8 milj. USD20222023: 0,00 milj. USD2023: EBIT −2,4 milj. USD20232024: 0,00 milj. USD2024: EBIT −2,0 milj. USD20242025: 0,00 milj. USD2025: EBIT −2,3 milj. USD20250,00−2,3
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Hemostatic gauze70 %

Cotton-based gauze designed to absorb drainage and help control bleeding.

Wound care dressings20 %

Superficial wound and external bleeding products used in healthcare settings.

Branded surgical/wound formats10 %

Product formats and trademarks associated with the company’s gauze platform.

Asiakkaat

The company’s target customers are healthcare providers that need products for bleeding control and wound management, especially hospitals, surgery centers, clinics, and physicians. Its stated commercial focus also includes the broader human surgical market, where Class III-approved hemostatic agents are used in more demanding procedures.

Hospitals and surgery centers

Buy hemostatic gauze for internal surgical bleeding control and procedural use.

Clinics and physicians

Use the products for superficial wounds, drainage absorption, and external bleeding.

Medical technology partners

May commercialize, distribute, or acquire the product platform.

Surgical device and wound care companies

Potential channel partners or strategic buyers for the product line.

Strategia

The company is focused on obtaining FDA pre-market approval for its CelluSTAT hemostatic gauze so it can address higher-value surgical markets. It is also evaluating commercialization partnerships, a sale, or a merger with an industry participant rather than building a large independent sales organization.

Obtain FDA PMA for CelluSTATLyhyt aikaväli

Regulatory approval is the key gate to the company’s intended surgical market expansion.

Secure commercialization partnerLyhyt aikaväli

A partner can provide distribution, market access, and execution capacity.

Maximize value through strategic transactionKeskipitkä aikaväli

Management has indicated a sale or merger may be the preferred long-term path.

Maantiede

The company is based in the United States, where its products are cut, packaged, and sterilized by service providers. Its stated commercial opportunity includes both domestic and international Class III human surgical markets, although the disclosed operating footprint in the excerpts is primarily U.S.-based.

Riskit

The company faces substantial regulatory risk because its core growth plan depends on FDA PMA approval, which cannot be assured. It also has going-concern and financing risk, since it has not yet generated operating revenue and depends on external funding to support development and regulatory work.

Järjestetty vakavuuden mukaan
FDA PMA not grantedKriittinen

The company’s surgical market strategy depends on approval for Class III use.

Kohdistuu: CelluSTAT and the Class III surgical market

Going-concern and liquidity constraintsKriittinen

The company has not yet reached operating scale sufficient to fund overhead internally.

Kohdistuu: Corporate funding and development operations

Dilution from equity financingKorkea

Future capital raises may be needed to fund regulatory and commercialization efforts.

Kohdistuu: Common stock issuance and convertible financing

Commercial execution dependence on partnersKorkea

The company does not intend to fully commercialize independently.

KohdistuuDistributionSalesMarket access
Competition in hemostatic and surgical device marketsKeskitaso

Established competitors may have stronger regulatory, sales, and hospital relationships.

Kohdistuu: Wound care and surgical hemostats

Kirjanpito

Harkinnanvaraiset erät
Stock-based compensation

Awards to employees and directors are expensed over the vesting period and can be material relative to revenue.

Vaikutus: Operating expenses and equity dilution

Going-concern assessment

Management and auditors must assess whether financing is sufficient to continue operations.

Vaikutus: Disclosure risk and financial statement presentation

Fair value of financing instruments

Equity-linked funding arrangements and related-party loans may require judgment in measurement and disclosure.

Vaikutus: Liabilities, equity, and financing costs

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Päivitetty: 24.9.2026

United Health Products, Inc. (OTC) – Orthopedic, Prosthetic & Surgical Applia | Analyysi – Clarifo